Latest news with #CoreDiagnostics
Time of India
14-05-2025
- Business
- Time of India
Metropolis Q4 net profit drops 19%, reports no margin gain from Core Diagnostics
Mumbai: Pathology laboratory chain Metropolis Healthcare reported a 19 per cent year-on-year (YoY) decline in net profit to ₹29 crore in the quarter ended March 2025. While the company revenue from operations went up 10 per cent YoY to ₹345 crore, both Profit (8.5 per cent) and adjusted EBITDA margins (24.3 per cent) reflected a dip against the corresponding period. As per the company investors presentation 'the reported EBITDA and PAT (Profit After Tax) were impacted due to one off expenses related to 3 acquisitions, Costs linked to legal and professional fees for tax cases and other small provisions for Inventory.' The company's profit and loss statement that from its total quarterly revenue it incurred a one-time expense of ₹21 crore. During the quarter the company reported 'NIL margin from one if its recent acquisition Core Diagnostics and lower than usual revenue in February in its focus markets.' In December the Pathology chain had acquired 100 per cent stakes of the Delhi-based Core Diagnostics for ₹246 crore. However, the company has maintained a positive outlook for its recent acquisitions. 'We are confident that our recent acquisitions will generate strong returns and fuel the next phase of growth. in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India.' Ameera Shah , Executive Chairperson and Whole-time Director, Metropolis Healthcare Limited, commented. For the full fiscal year the company revenue from operations went up 10 per cent YoY to ₹1,331 crore, while the net profit reported an increase of 14 per cent to ₹146 crore, against the previous fiscal. The current revenue ratio between the company's B2B and B2C services stands at 45:55 and in the last fiscal the two segments reported a YoY increase of 12 per cent and 17 per cent respectively. At the end of FY25 the company portfolio represents 210 clinical labs and is further looking to expand its network. 'With a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value,' said Shah. 'As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care,' Surendran Chemmenkotil, CEO, Metropolis Healthcare, added.
&w=3840&q=100)
Business Standard
13-05-2025
- Business
- Business Standard
Metropolis Healthcare Q4 results: Net profit falls 19.9%, revenue up 4.3%
India's second-largest pathology laboratory chain, Metropolis Healthcare, on Tuesday posted a 19.9 per cent year-on-year (YoY) decline in its consolidated net profit to ₹29.1 crore for Q4FY25, while revenue from operations rose 4.32 per cent to ₹345.2 crore. The decline in profit was attributed to one-off expenses related to three acquisitions, legal and professional fees concerning tax matters, and a minor provision for inventory. For FY25, Metropolis reported a 13.4 per cent YoY increase in net profit, reaching ₹144.9 crore compared to ₹127.8 crore in FY24. Revenue from operations grew 10.2 per cent to ₹1,331.2 crore, up from ₹1,207.7 crore in FY24. The increase in annual net profit was driven by rising demand for preventive and specialised testing. On a sequential basis, the company's revenue rose 6.9 per cent, while profit after tax (PAT) declined 7 per cent. Commenting on future plans, Ameera Shah, Executive Chairperson and Whole-time Director, Metropolis Healthcare, said: 'Our growth was fuelled by rising demand for preventive and specialised testing, enabled by focused execution, stronger clinician engagement, and innovation. We introduced industry-first cancer screening panels and tools, along with AI-powered diagnostics to enhance accuracy and enable early detection.' In FY25, patient volume increased by 6 per cent YoY, and test volume rose 7 per cent. Revenue per patient grew 6 per cent, supported by pricing revisions and upselling strategies at the micro-market level. The business-to-consumer (B2C) revenue rose 17 per cent YoY in FY25 and 14 per cent in Q4FY25, driven by ongoing initiatives to improve the consumer interface and expand the service network. The business-to-business (B2B) revenue rose 12 per cent YoY in FY25 and 10 per cent in Q4FY25, supported by service delivery changes and stronger partner engagement. On future growth, Shah added: 'We are confident that our recent acquisitions — Core Diagnostics, Scientific Pathology, and Dr Ahuja's Pathology & Imaging Centre — will generate strong returns and fuel the next phase of growth. These acquisitions expand our B2C footprint and strengthen our regional presence in North India.' The firm's wellness programme, TruHealth, saw revenue grow 24 per cent YoY in FY25, with Q4 accounting for 19 per cent of the full-year revenue. The speciality diagnostics segment recorded a 13 per cent YoY increase in FY25. Revenue from Tier III cities accounted for 18 per cent of overall revenue during the year. The company expanded its reach to over 750 towns, adding 29 laboratories and 400 collection centres in FY25. Metropolis Healthcare's stock fell 0.66 per cent to ₹1,701.85 apiece on the BSE. The results were announced after market hours on Tuesday.
